Lopez-Quintero C, Roth KB, Eaton WW, Wu L, Cottler LB, Bruce M, et al. Mortality among heroin users and users of other internationally regulated drugs: a 27-year follow-up of users in the Epidemiologic Catchment Area Program household samples. Drug Alcohol Depend. 2015;156:104–11. https://doi.org/10.1016/j.drugalcdep.2015.08.030.
van Amsterdam J, Nutt D, Phillips L, van den Brink W. European rating of drug harms. J Psychopharmacol. 2015;29:655–60. https://doi.org/10.1177/0269881115581980.
UNODC. World Drug Report Executive summary. Conclusions and Policy Implications. Vienna: United Nations Office on Drugs and Crime; 2018.
Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Heal. 2017;5:1–13. https://doi.org/10.1016/S2214-109X(17)30373-X.
UNAIDS. Health, rights and drugs. Harm reduction, decriminalization and zero discrimination for people who use drugs. 2019.
Stahl S. Stahl’s essential pscyhopharmacology. Cambridge: Cambridge University Press; 2013.
Somer E, Avni R. Dissociative phenomena among recovering heroin users and their relationship to duration of abstinence. J Soc Work Pract Addict. 2003;3:25–38. https://doi.org/10.1300/J160v03n01_03.
Valentine K, Fraser S. Trauma damage and pleasure: Rethinking problematic drug use. Int J Drug Policy. 2008;19:410–6.
Schindler A, Thomasius R, Petersen K, Sack P-M. Heroin as an attachment substitute? Differences in attachment representations between opioid, ecstasy and cannabis abusers. Attach Hum Dev. 2009;11:307–30. https://doi.org/10.1080/14616730902815009.
Kaiko RF, Wallenstein SL, Rogers AG, Grabinski PY, Houde RW. Analgesic and mood effects of heroin and morphine in cancer patients with postoperative pain. N Engl J Med. 1981;304:1501–5. https://doi.org/10.1056/NEJM198106183042501.
WHO. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: World Health Organization; 2009.
Beg M, Strathdee SA, Kazatchkine M. State of the Art Science addressing Injecting Drug Use, HIV and Harm Reduction. Int J Drug Policy. 2014. https://doi.org/10.1016/j.drugpo.2014.11.008.
World Health Organization, United Nations Office on Drugs and Crime, Joint United Nations Programme on HIV/AIDS. Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention. Position paper. 2004; 1–33.
Caplehorn JR, Dalton MS, Haldar F, Petrenas AM, Nisbet JG. Methadone maintenance and addicts’ risk of fatal heroin overdose. Subst Use Misuse. 1996;31:177–96.
Wilson DP, Donald B, Shattock AJ, Wilson D, Fraser-Hurt N. The cost-effectiveness of harm reduction. Int J Drug Policy. 2015;26:S5–11. https://doi.org/10.1016/j.drugpo.2014.11.007.
Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007;11:1–171.
Kourounis G, Richards BDW, Kyprianou E, Symeonidou E, Malliori M-M, Samartzis L. Opioid substitution therapy: lowering the treatment thresholds. Drug Alcohol Depend. 2016;161:1–8. https://doi.org/10.1016/j.drugalcdep.2015.12.021.
Christie TKS, Murugesan A, Manzer D, Shaughnessey MVO, Webster D. Evaluation of a low-threshold / high-tolerance methadone maintenance treatment clinic in saint john, new Brunswick, Canada: 1 year retention rate and illicit drug use. J Addict. 2013;13:1–5. https://doi.org/10.1155/2013/753409.
Torrens M, Castillo C, Pérez-Solá V. Retention in a low-threshold methadone maintenance program. Drug Alcohol Depend. 1996;41:55–9. https://doi.org/10.1016/0376-8716(96)01230-6.
Harris J, McElrath K. Methadone as Social Control. Qual Health Res. 2012;22:810–24.
Gourlay J, Ricciardelli L, Ridge D. Users’ experiences of heroin and methadone treatment. Subst Use Misuse. 2005;40:1875–82.
Scheibe A, Marks M, Shelly S, Gerardy T, Domingo A, Hugo J. Developing an advocacy agenda for increasing access to opioid substitution therapy as part of comprehensive services for people who use drugs in South Africa. S Afr Med J. 2018;108:800–2.
United Nations Office on Drugs and Crime. World Drug Report 2015. Vienna: United Nations Office on Drugs and Crime; 2015.
United Nations Office on Drugs and Crime. UNODC 2018 Prevalence of drug use in the general population–national data. Vienna: United Nations Office on Drugs and Crime; 2018.
Statistics South Africa. Mid-year population estimates 2018. Statistical release P0302. Pretoria: Statistics South Africa; 2018.
Dada S, Harker Burnhams N, Erasmus J, Parry C, Bhana A, Kitshoff D, et al. Monitoring alcohol, tobacco and other drug use trends in South Africa. Res Brief. 2017;20:1–9.
Howell S, Harker-Burnhams N, Townsend L, Shaw M. The wrong type of decline: fluctuations in price and value of illegal substances in Cape Town. SA Crime Q. 2015;54(1):43–544.
Weich L. Defeating the dragon–can we afford not to treat patients with heroin dependence? S Afr J Psychiatry. 2010;16:75–9.
Michie G, Hoosain S, Macharia M, Weich L. Report on the first government-funded opioid substitution programme for heroin users in the Western Cape Province, South Africa. S Afr Med J. 2017;107:539–42.
World Health Organization. Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations. Geneva: World Health Organization; 2016.
Scheibe A, Shelly S, Versfeld A, Howell S, Marks M. Safe treatment and treatment of safety: call for a harm-reduction approach to drug-use disorders in South Africa. S Afr Health Rev. 2017;20:197–204.
van Dyk J. Durban cuts city’s only needle exchange programme. Bhekisisa. 2018. https://bhekisisa.org/article/2018-05-30-00-durban-cuts-citys-only-needle-exchange-programme/. Accessed 30 Nov 2019.
Scheibe A, Matima R, Schneider A, Basson R, Ngcebetsha S, Padayachee K, et al. Still left behind: harm reduction coverage and HIV treatment cascades for people who inject drugs in South Africa. In: 10th IAS Conference on HIV Science. Mexico; 2019.
South African National Department of Health. Standard treatment guidelines and essential medicines list for South Africa. Hospital level. 3rd ed. Pretoria: Department of Health; 2012.
International Narcotics Control Board. Narcotic drugs 2018. Estimated requirements for 2019. Statistics for 2017. 2018; 1–494. https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2018/INCB-Narcotics_Drugs_Technical_Publication_2018.pdf.
Weich L. Defeating the dragon—can we afford not to treat patients with heroin dependence? S Afr J Psychiatry. 2010. https://doi.org/10.4102/sajpsychiatry.v16i3.260.
National Department of Health. Standard treatment guidelines and essential medicines list for South Africa: primary healthcare level. 2018th ed. Pretoria: South African National Department of Health; 2018.
Harm Reduction International. The Global state of harm reduction 2018. 6th ed. London: Harm Reduction International; 2018.
World Health Organization. The alcohol smoking and substance involvement screening test. Geneva: World Health Organization; 2010.
Weich L, Nowbath H, Flegar S, Mahomedy Z, Ramjee H, Hitzeroth V, et al. South African guidelines for the management of opioid dependence. Updated 2013. 2013.
Weich L, Perkel C, van Zyl N, Rataemane P, Naidoo L, Nowbath H, et al. South African guidelines for the management of opioid dependence. S Afr Addict Med Soc. 2013;100:1–18.
Quality Metric Incorporated. User’s manual for the SF-12v2 Health survey. 3rd ed. Quality Metric Incorporated: Lincoln; 2012.
Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev. 2010;30:155–66.
Bell J. Pharmacological maintenance treatments of opiate addiction. Br J Clin Pharmacol. 2014;77:253–63.
Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35:22–35. https://doi.org/10.1080/10550887.2016.1100960.
Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet. 1999;353:221–6. https://doi.org/10.1016/S0140-6736(98)05356-2.
Feelemyer J, Des Jarlais D, Arasteh K, Abdul-Quader AS, Hagan H. Retention of participants in medication-assisted programs in low- and middle-income countries: an international systematic review. Addiction. 2014;109:20–322. https://doi.org/10.1111/add.12303.
Connery HS. Medication-assisted treatment of opioid use disorder. Harv Rev Psychiatry. 2015;23:63–75. https://doi.org/10.1097/HRP.0000000000000075.
Akindipe T, Abiodun L, Adebajo S, Lawal R, Rataemane S. From addiction to infection: managing drug abuse in the context of HIV/AIDS in Africa. Afr J Reprod Health. 2014;18(3):47–544.
Brorson HH, Ajo Arnevik E, Rand-Hendriksen K, Duckert F. Drop-out from addiction treatment: a systematic review of risk factors. Clin Psychol Rev. 2013;33:1010–24. https://doi.org/10.1016/j.cpr.2013.07.007.
Yang F, Lin P, Li Y, He Q, Long Q, Fu X, et al. Predictors of retention in community-based methadone maintenance treatment program in Pearl River Delta. China Harm Reduct J. 2013;10:3. https://doi.org/10.1186/1477-7517-10-3.
Walley AY, Cheng DM, Pierce CE, Chen C, Filippell T, Samet JH, et al. Methadone dose, take home status, and hospital admission among methadone maintenance patients. J Addict Med. 2012;6:186–90.
Garcia-Portilla MP, Bobes-Bascaran MT, Bascaran MT, Saiz PA, Bobes J. Long term outcomes of pharmacological treatments for opioid dependence: does methadone still lead the pack? Br J Clin Pharmacol. 2014;77:272–84. https://doi.org/10.1111/bcp.12031.
Villafranca SW, McKellar JD, Trafton JA, Humphreys K. Predictors of retention in methadone programs: a signal detection analysis. Drug Alcohol Depend. 2006;83:218–24.
Lo A, Kerr T, Hayashi K, Milloy MJ, Nosova E, Liu Y, et al. Factors associated with methadone maintenance therapy discontinuation among people who inject drugs. J Subst Abuse Treat. 2018;94:41–6. https://doi.org/10.1016/j.jsat.2018.08.009.
Smolka M, Schmidt LG. The influence of heroin dose and route of administration on the severity of the opiate withdrawal syndrome. Addiction. 1999;94:1191–8.
Shen L, Assanangkornchai S, Liu W, Cai L, Li F, Tang S, et al. Influence of social network on drug use among clients of methadone maintenance treatment centers in Kunming China. PLoS ONE. 2018;13:e0200105. https://doi.org/10.1371/journal.pone.0200105.
Kwan TH, Wong NS, Lee SS. Participation dynamics of a cohort of drug users in a low-threshold methadone treatment programme. Harm Reduct J. 2015;12:30. https://doi.org/10.1186/s12954-015-0072-z.
Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2011. https://doi.org/10.1002/14651858.CD004147.pub4.
Amato L, Davoli M, Minozzi S, Ferroni E, Ali R, Ferri M. Methadone at tapered doses for the management of opioid withdrawal. Cochrane database Syst Rev. 2013;2:CD003409.
Lingford-Hughes AR, Welch S, Peters L, Nutt DJ, et al. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol. 2012;26:899–952.
Van Den Brink WW, Haasen C. Evidenced-based treatment of opioid-dependent patients. Can J Psychiatry-Revue Can Psychiatr. 2006;51:635–46.
Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A Meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008;165:179–87. https://doi.org/10.1176/appi.ajp.2007.06111851.
Mattick RP, Breen C, Kimber J, Davoli M, Richard PM, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207.
DA W, MG W, BE H, SM H. Factors associated with lapses to heroin use during methadone maintenance. Drug Alcohol Depend. 1998;52:183–92. https://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&NEWS=N&AN=1998393995.
Franklyn AM, Eibl JK, Gauthier GJ, Pellegrini D, Lightfoot NE, Marsh DC. The impact of cocaine use in patients enrolled in opioid agonist therapy in Ontario, Canada. Int J Drug Policy. 2017;48:1–8. https://doi.org/10.1016/j.drugpo.2017.05.044.
Epstein DH, Preston KL. Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against. [comment] [erratum appears in Addiction. 2003 Apr 98(4):538]. Addiction. 2003;98:269–79.
Socías ME, Wood E, Lake S, Nolan S, Fairbairn N, Hayashi K, et al. High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis. Addiction. 2018;113:2250–8.
Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010;376:1558–65.
The Constitutional Court of South Africa. Minister of justice and constitutional development and others v prince (Clarke, Stobbs and Thorpe Intervening) (Doctors of Life International Inc as Amicus Curiae); National Director of Public Prosecutions and Others v Rubin; National Director of Public P. 2018. https://hdl.handle.net/20.500.12144/34547.
Dada S, Harker N, Jodilee B, Warren E, Parry C, Bhana A, et al. April 2019 Phase 44. Cape Town: SA Medical Research Council; 2019.
UNODC, UNWOMEN, WHO, INPUD. Women who inject drugs and HIV: addressing specific needs issue summary: the key reasons and unique challenges. Policy brief. 2014.
Dannatt L, Cloete KJ, Kidd M, Weich L. Frequency and correlates of comorbid psychiatric illness in patients with heroin use disorder admitted to Stikland Opioid Detoxification Unit, South Africa. S Afr J Psychiatry. 2014;20:77.
Morgan N, Daniels W, Subramaney U. A prospective observational study of heroin users in Johannesburg, South Africa: assessing psychiatric comorbidities and treatment outcomes. Compr Psychiatry. 2019. https://doi.org/10.1016/j.comppsych.2019.152137.